BlackRock, Inc. 13D and 13G filings for Akero Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-01-26 11:49 am Purchase |
2023-12-31 | 13G | Akero Therapeutics, Inc. AKRO |
BLACKROCK INC BLK |
4,180,507 7.500% |
1,421,978 (+51.55%) |
Filing |
| 2023-02-03 12:09 pm Purchase |
2022-12-31 | 13G | Akero Therapeutics, Inc. AKRO |
BLACKROCK INC BLK |
2,758,529 5.900% |
494,286 (+21.83%) |
Filing |
| 2022-11-09 2:21 pm Purchase |
2021-10-31 | 13G | Akero Therapeutics, Inc. AKRO |
BLACKROCK INC BLK |
2,264,243 4.900% |
320,121 (+16.47%) |
Filing |
| 2022-11-09 1:53 pm Purchase |
2021-10-31 | 13G | Akero Therapeutics, Inc. AKRO |
BLACKROCK INC BLK |
2,264,243 4.900% |
2,264,243 (New Position) |
Filing |
| 2022-02-04 4:12 pm Purchase |
2021-12-31 | 13G | Akero Therapeutics, Inc. AKRO |
BLACKROCK INC BLK |
1,944,122 5.600% |
1,944,122 (New Position) |
Filing |